Axq Capital, LP Arcus Biosciences, Inc. Transaction History
Axq Capital, LP
- $222 Billion
- Q4 2024
A detailed history of Axq Capital, LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 10,761 shares of RCUS stock, worth $97,817. This represents 0.07% of its overall portfolio holdings.
Number of Shares
10,761Holding current value
$97,817% of portfolio
0.07%Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.2MCall Options Held
288KPut Options Held
138K-
Black Rock Inc. New York, NY9.76MShares$88.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.39MShares$49 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.52MShares$32 Million0.39% of portfolio
-
State Street Corp Boston, MA2.99MShares$27.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2MShares$18.1 Million0.07% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $656M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...